Polat M, et al. - This study is undertaken to assess the clinical and microbiological outcomes of community-acquired lower urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing E. coli treated with outpatient amikacin in children. In pediatric patients with normal renal function, once-daily intramuscular amikacin can be an alternative option for outpatient treatment of community-acquired lower UTIs caused by amikacin-susceptible ESBL-producing E. coli, when there are no suitable oral antibiotics.